| CRH |
Report |
Adj. EBITDA (Q2 2026) |
BEAT |
pred ~$2.65B vs. cons $2.60B |
MEDIUM |
| CRH |
Report |
Total Revenue (Q2 2026) |
BEAT |
pred ~$10.95B vs. cons $10.71B |
MEDIUM |
| CRH |
Report |
Diluted Op. EPS (Q2 2026) |
BEAT |
pred ~$2.10 vs. cons $2.06 |
MEDIUM |
| CRH |
Guide |
FY 2026 Adj. EBITDA (FY 2026) |
UNCHANGED |
guide ~$8.3B mid (reaffirm) vs. cons $8.30B |
MEDIUM |
| CRH |
Guide |
H2 2026 Implied EBITDA (H2 2026) |
LOWER |
guide ~$5.07B implied vs. cons $5.12B |
MEDIUM |
| CRH |
Return |
Day-1 residual (stock − beta × S&P 500) |
-0.5% |
— |
MEDIUM |
| CRH |
Return |
5-day cumulative residual |
-2.5% (FADE) |
FADE — H2 estimate cuts materialize as sell-side works through FY guide math post-print |
MEDIUM |